Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Molecular Partners AG - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
MOLN
Nasdaq
2836
www.molecularpartners.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Molecular Partners AG
Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference
- Jan 12th, 2025 6:00 pm
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
- Jan 12th, 2025 6:00 pm
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
- Dec 17th, 2024 9:00 pm
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet
- Dec 13th, 2024 2:55 pm
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
- Dec 8th, 2024 5:00 pm
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
- Nov 7th, 2024 9:00 pm
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
- Nov 5th, 2024 9:00 pm
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
- Oct 31st, 2024 8:00 pm
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
- Oct 25th, 2024 5:00 am
Molecular Partners Expands Radio-DARPin Collaboration
- Oct 23rd, 2024 1:29 pm
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
- Oct 22nd, 2024 5:00 am
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
- Oct 22nd, 2024 5:00 am
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
- Oct 4th, 2024 5:00 am
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
- Sep 27th, 2024 5:00 am
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
- Aug 26th, 2024 8:00 pm
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
- Jun 17th, 2024 5:00 am
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
- Jun 14th, 2024 5:00 am
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
- Jun 11th, 2024 5:00 am
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
- Jun 1st, 2024 12:00 pm
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
- May 16th, 2024 8:00 pm
Scroll